Published data to date indicate that human papillomavirus (HPV) prevention vaccines are safe and efficacious in reducing HPV persistence and cervical intraepithelial neoplasia grade 2/3 lesions of the cervix ([1][1]-[5][2]). The U.S. Food and Drug Administration licensed the quadrivalent HPV vaccine
No takes yet. Share an insight, caveat, or question.
Giuliano et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: